skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi 5I team.
My question is about healthcare and diversification in the space. I have been attempting to keep my position around the 16% portfolio weighting and currently hold ABBV, AMD, AMGN(4.8%), LLY(3%), PFE, MRNA, and WELL positions. Although I do not want to abandon the PFE/MRNA freight trains, I am looking at adding/shifting to what may be a longer term/higher dividend return avenue with the use of GILD(attractive entry and solid div), CRISPR(awaiting a pull back to $90 if it comes), and even MDT(under $103 if it comes)

How do you feel about this strategy and the switch out of AMGN/LLY to GILD/MDT?

Thank you

Peter
Read Answer Asked by Peter on November 23, 2020
Q: This week Pfizer spun-out Viatris as a Reverse Morris Trust Transaction. I understand the purpose of this type of transaction is to make it non-taxable. Are there income tax consequences for a Canadian citizen who owned Pfizer at the time of the spin-out?
Are Viatris shares worth holding?
Read Answer Asked by Ken on November 20, 2020
Q: I have been holding BIIB for a couple of years on hopes (I know, that is not an investment strategy) that their alzheimer drug would be approved. It has come close a few times and the stock has reacted very favourably only to fall short of approval and fall back in price. Do you believe that the recent setback will make BIIB dead money for the foreseeable future and its best to move on or is it too cheap and compelling a story to sell now? If BIIB was part of your US Growth portfolio would you keep it or sell in favour of a better growth stock. If your decision would be to sell, what would be the top 2 names for replacement with no regard to sector.

Thanks
Scott
Read Answer Asked by Scott on November 19, 2020
Q: Hi 5i,
In their latest quarter results, they did beat the estimates. Remdesivir is still a one of the most used drug treatment. My opinion is that it will still be continued to be used for treatment till a better one is found.
Not sure why market is not so excited about the results and future prospects. Can you clarify.
Thanks for your sound advise.
Read Answer Asked by Vinod on November 17, 2020
Q: I am interested why you would recommend Cloud MD (Doc). Is it because it's share price has increased by the graces of companies like Teladoc and Well, or do you think their promotional approach will result in a successful business model? I am old enough to remember Patient Home Monitoring (phm). Similarities here?
Read Answer Asked by Rashida on November 16, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!